Credit Suisse Reiterates Neutral on Teladoc Health, Maintains $27 Price Target
Portfolio Pulse from richadhand@benzinga.com
Credit Suisse analyst Jonathan Yong has reiterated a Neutral rating on Teladoc Health (NYSE:TDOC) and maintained a $27 price target.
July 26, 2023 | 1:04 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Credit Suisse has reiterated a Neutral rating on Teladoc Health, maintaining a $27 price target.
The reiteration of a Neutral rating by Credit Suisse indicates that the analyst sees the stock as fairly valued at current levels. The maintained price target of $27 suggests that the analyst does not expect significant price movement in the short term. This could lead to a neutral impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100